The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie's disease

International Urology and Nephrology

Volumn 41, Issue 1, 2009, Pages 113-118

  Tuygun, Can ^a   Ozok, Ugur Hakki ^a   Gucuk, Adnan ^a   Halil Bozkurt, I ^a   Abdurrahim Imamoglu, M ^a  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Dexamethasone; Iontophoresis; Peyronie's disease; Verapamil

Indexed keywords

DEXAMETHASONE; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; ELECTRODE; ERECTILE DYSFUNCTION; HUMAN; MALE; OUTCOME ASSESSMENT; PAINFUL ERECTION; PATIENT ASSESSMENT; PENIS ERECTION; PEYRONIE DISEASE; PROSPECTIVE STUDY; SEXUAL BEHAVIOR; SYMPTOM; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CALCIUM CHANNEL BLOCKERS; DEXAMETHASONE; ELECTROCHEMOTHERAPY; HUMANS; MALE; MIDDLE AGED; PENILE INDURATION; PROSPECTIVE STUDIES; VERAPAMIL;

EID: 62349133115     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-008-9408-x     Document Type: Article

References (31)

1. Tefekli A, Kandirali E, Erol H, Alp T, Köksal T, Kadioǧlu A (2001) Peyronie's disease in men under age 40: Characteristics and outcome. Int J Impot Res 13(1):18-23
2. Mulhall JP, Creech SD, Boorjian SA (2004) Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 171(6 Pt 1):2350-2353
3. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U (2001) The prevalence of Peyronie's disease: Results of a large survey. BJU Int 88(7):727-730
4. Hellstrom WJ, Bivalacqua TJ (2000) Peyronie's disease: Etiology, medical, and surgical therapy. J Androl 21(3):347-354
5. Devine CJ, Somers KD, Ladaga LE (1991) Peyronie's disease: pathophysiology. Prog Clin Biol Res 370:355-358
6. Levine LA, Merrick PF, Lee RC (1994) Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 151(6):1522-1524
7. Devine CJ, Somers KD, Jordan SG, Schlossberg SM (1997) Proposal: Trauma as the cause of the Peyronie's lesion. J Urol 157:285-290
8. Jarow JP, Lowe FC (1997) Penile trauma: An etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 158:1388-1390
9. Van de Water L (1997) Mechanisms by which fibrin and fibronectin appear in healing wounds: Implications for Peyronie's disease. J Urol 157:306-310
10. Bour H (1984) Current status of vitamin E. Rev Prat 34:1270-1271
11. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP (1992) The treatment of Peyronie's disease with tamoxifen. Br J Urol 70(6):648-651
12. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF (1994) Is colchicine effective in Peyronie's disease? A pilot study. Urology 44(2):291-295
13. Carson CC (1997) Potassium para-aminobenzoate for the treatment of Peyronie's disease: Is it effective? Tech Urol 3:135-139
14. Fitkin J, Ho GT (1999) Peyronie's disease: Current management. Am Fam Physician 60(2):549-552
15. Weidner W, Hauck EW, Schnitker J (2005) Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: A prospective, placebo-controlled, randomized study. Eur Urol 47(4):530-535
16. Gelbard MK, Dorey F, James K (1990) The natural history of Peyronie's disease. J Urol 144:1376-1379
17. Tunuguntla HS (2001) Management of Peyronie's disease - a review. World J Urol 19:244-250
18. Levine LA (1997) Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 158:1395-1399
19. Rehman J, Benet A, Melman A (1998) Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long-term single-blind study. Urology 51:620-626
20. Levine LA, Goldman KE, Greenfield JM (2002) Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 168(2):621-625
21. Hellstrom WJ, Kendirci M, Matern R (2006) Single-blind, multicenter, placebo controlled paralel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 176(1):394-398
22. Gelbard MK, James K, Riach P, Dorey F (1993) Collagenase versus placebo in the treatment of Peyronie's disease: A double-blind study. J Urol 149(1):56-58
23. Ludwig G (1991) Evaluation of conservative therapeutic approaches to Peyronie's disease (fibrotic induration of the penis). Urol Int 47(4):236-239
24. Riedl CR, Plas E, Engelhardt P, Daha K, Pflüger H (2000) Iontophoresis for treatment of Peyronie's disease. J Urol 163(1):95-99
25. Montorsi F, Salonia A, Guazzoni G (2000) Transdermal electromotive multi-drug administration for Peyronie's disease: Preliminary results. J Androl 21:85-90
26. Di Stasi SM, Giannantoni A, Capelli G (2003) Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int 91:825-829
27. Di Stasi SM, Giannantoni A, Stephen RL (2004) A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 171:1605-1608
28. Greenfield JM, Shah SJ, Levine LA (2007) Verapamil versus saline in electromotive drug administration for Peyronie's disease: A double-blind, placebo controlled trial. J Urol 177(3):972-975
29. Mulhall JP, Anderson MS, Lubrano T, Shankey TV (2002) Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses. Int J Impot Res 14(5):397-405
30. Martin DJ, Badwan K, Parker M, Mulhall JP (2002) Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 168(6):2483-2485
31. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S (2002) A retrospective review of 307 men with Peyronie's disease. J Urol 168(3):1075-1079